Ultragenyx Pharmaceutical Exec Says U.S. Per Patient Wholesale Acquisition Cost For Fayuvi Is Set At $3.95M
https://event.choruscall.com/mediaframe/webcast.html?webcastid=1t78iDYA
Share
Why It Matters
Ultragenyx set the price for their new medicine Fayuvi at $3.95 million per patient. This tells you how the company plans to make money from this drug.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.